Difference between revisions of "Cyclophosphamide (Cytoxan)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Intravenous chemotherapy" to "Category:Intravenous medications") |
m |
||
| Line 55: | Line 55: | ||
==Also known as== | ==Also known as== | ||
| + | *'''Code names:''' Asta B 518, B-518, WR-138719 | ||
| + | *'''Generic names:''' CP monohydrate, CPM, cyclophosphamid monohydrate, cyclophosphamide monohydrate | ||
| + | *'''Brand names:''' | ||
{| border="1" style="text-align:center;" | {| border="1" style="text-align:center;" | ||
!colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms''' | !colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms''' | ||
| Line 62: | Line 65: | ||
|Carloxan | |Carloxan | ||
|Ciclofosfamida | |Ciclofosfamida | ||
| − | |||
| − | |||
|Ciclokebir | |Ciclokebir | ||
| + | |Cicloxal | ||
| + | |Clafen | ||
| + | |Claphene | ||
| + | |- | ||
|Cyclam | |Cyclam | ||
| − | |||
|Cycloblastin | |Cycloblastin | ||
|Cycloblastine | |Cycloblastine | ||
| − | | | + | |CYCLO-cell |
|Cycloferon | |Cycloferon | ||
|Cyclomide | |Cyclomide | ||
|Cyclophar | |Cyclophar | ||
|Cyclophospham | |Cyclophospham | ||
| + | |- | ||
|Cyclophosphamid | |Cyclophosphamid | ||
| − | | | + | |Cyclophosphane |
| − | |||
| − | |||
| − | |||
| − | |||
|Cyclostin | |Cyclostin | ||
| + | |Cyclostine | ||
| + | |Cyclotox | ||
|Cycloxan | |Cycloxan | ||
|Cycram | |Cycram | ||
| Line 86: | Line 89: | ||
|- | |- | ||
|Cyklofosfamid | |Cyklofosfamid | ||
| + | |Cyphos | ||
|Cytophosphan | |Cytophosphan | ||
|Cytoxan | |Cytoxan | ||
| Line 92: | Line 96: | ||
|Endoxan-N | |Endoxan-N | ||
|Endoxana | |Endoxana | ||
| − | |||
|- | |- | ||
| + | |Enduxan | ||
|Formitex | |Formitex | ||
| + | |Fosfaseron | ||
|Genoxal | |Genoxal | ||
|Genuxal | |Genuxal | ||
| Line 100: | Line 105: | ||
|Ledoxan | |Ledoxan | ||
|Ledoxina | |Ledoxina | ||
| − | | | + | |- |
| + | |Mitoxan | ||
| + | |Neophos | ||
|Neosar | |Neosar | ||
| − | |||
|Oncomide | |Oncomide | ||
|Oncophos | |Oncophos | ||
| Line 108: | Line 114: | ||
|Revimmune | |Revimmune | ||
|Sendoxan | |Sendoxan | ||
| + | |- | ||
| + | |Siklofos | ||
|Syklofosfamid | |Syklofosfamid | ||
| − | |||
|Tymtran | |Tymtran | ||
| − | | | + | |Zuviphos |
|Zycram | |Zycram | ||
| + | |Zytoxan | ||
|} | |} | ||
| Line 119: | Line 127: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | |||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| + | [[Category:Oral medications]] | ||
[[Category:Irritant chemotherapy]] | [[Category:Irritant chemotherapy]] | ||
[[Category:Neutral chemotherapy]] | [[Category:Neutral chemotherapy]] | ||
| − | |||
[[Category:Alkylating agents]] | [[Category:Alkylating agents]] | ||
| Line 168: | Line 175: | ||
[[Category:Drugs FDA approved in 1959]] | [[Category:Drugs FDA approved in 1959]] | ||
| + | [[Category:PMDA approved drugs]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 02:23, 10 August 2017
General information
Class/mechanism: Alkylating agent; transformed primarily in the liver to active metabolites which alkylate and crosslink DNA.[1][2]
Route: IV, PO
Extravasation: irritant or neutral, depending on reference; n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adult T-cell leukemia-lymphoma
- Anaplastic large cell lymphoma
- B-cell acute lymphoblastic leukemia
- Bladder cancer
- Bone cancer
- Breast cancer
- Burkitt lymphoma
- Central nervous system (CNS) cancer
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- CNS lymphoma
- Coagulopathies
- Diffuse large B-cell lymphoma
- Ewing's sarcoma
- Follicular lymphoma
- Glioblastoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Large granular lymphocytic leukemia
- Light-chain (AL) amyloidosis
- Mantle cell lymphoma
- Marginal zone lymphoma
- Mediastinal gray-zone lymphoma
- Multiple myeloma
- Neuroendocrine tumors
- Osteosarcoma
- Peripheral T-cell lymphoma
- Plasma cell leukemia
- Post-transplant lymphoproliferative disorder
- Primary mediastinal B-cell lymphoma
- Prostate cancer
- Small cell lung cancer
- T-cell acute lymphoblastic leukemia
- Thymoma
- Transformed lymphoma
- Transplant conditioning regimens
- Waldenström macroglobulinemia
Patient drug information
- Cyclophosphamide (Cytoxan) patient drug information (Chemocare)[3]
- Cyclophosphamide (Cytoxan) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 11/16/1959: initial FDA approval
Also known as
- Code names: Asta B 518, B-518, WR-138719
- Generic names: CP monohydrate, CPM, cyclophosphamid monohydrate, cyclophosphamide monohydrate
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Alkyloxan | Biodoxan | Carloxan | Ciclofosfamida | Ciclokebir | Cicloxal | Clafen | Claphene |
| Cyclam | Cycloblastin | Cycloblastine | CYCLO-cell | Cycloferon | Cyclomide | Cyclophar | Cyclophospham |
| Cyclophosphamid | Cyclophosphane | Cyclostin | Cyclostine | Cyclotox | Cycloxan | Cycram | Cydoxan |
| Cyklofosfamid | Cyphos | Cytophosphan | Cytoxan | Cytoxan Lyophilized | Endoxan | Endoxan-N | Endoxana |
| Enduxan | Formitex | Fosfaseron | Genoxal | Genuxal | Hidrofosmin | Ledoxan | Ledoxina |
| Mitoxan | Neophos | Neosar | Oncomide | Oncophos | Procytox | Revimmune | Sendoxan |
| Siklofos | Syklofosfamid | Tymtran | Zuviphos | Zycram | Zytoxan | ||
References
Categories:
- Drug index
- Intravenous medications
- Oral medications
- Irritant chemotherapy
- Neutral chemotherapy
- Alkylating agents
- Nitrogen mustards
- Immunosuppresants
- Adult T-cell leukemia-lymphoma medications
- Anaplastic large cell lymphoma medications
- B-cell acute lymphoblastic leukemia medications
- Bladder cancer medications
- Bone cancer medications
- Breast cancer medications
- Burkitt lymphoma medications
- Central nervous system (CNS) cancer medications
- Central nervous system (CNS) lymphoma medications
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Coagulopathy medications
- Diffuse large B-cell lymphoma medications
- Ewing's sarcoma medications
- Follicular lymphoma medications
- Glioblastoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Large granular lymphocytic leukemia medications
- Light-chain (AL) amyloidosis medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Multiple myeloma medications
- Neuroendocrine tumor medications
- Osteosarcoma medications
- Peripheral T-cell lymphoma medications
- Plasma cell leukemia medications
- Post-transplant lymphoproliferative disorder medications
- Primary mediastinal B-cell lymphoma medications
- Prostate cancer medications
- Small cell lung cancer medications
- T-cell acute lymphoblastic leukemia medications
- Thymoma medications
- Transformed lymphoma medications
- Transplant medications
- Waldenström macroglobulinemia medications
- Drugs FDA approved in 1959
- PMDA approved drugs
- WHO Essential Cancer Medicine